Making mAb Accessible webinar

The Global HIV Vaccine Enterprise at the International AIDS Society and IAVI are pleased to invite you to join a webinar to discuss challenges and opportunities on the Access to future monoclonal antibodies for HIV prevention:

“Making monoclonal antibodies broadly accessible to communities most at risk of HIV/AIDS – What would it take?’’

HVTN 084 – Injectable HIV drug prevents infections

The IAS hosted Global HIV Vaccine Enterprise welcomes interim results showing effectiveness of long-acting injectable PrEP. New results announced today by ViiV healthcare show that injection of long-acting pre-exposure prophylaxis (PrEP) cabotegravir every two months is 89% more effective than a daily Truvada oral pill in a trial of women at increased risk of HIV acquisition.